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Abstract 
In this brief communication, additional computational validation is provided consistent with 
the unifying hypothesis that a shared biological mechanism of mesenchymal transition, 
reflected by a precise gene expression signature, may be present in all types of solid cancers 
when they reach a particular stage of invasiveness. 
 
Introduction 
We recently identified a signature consisting of a set of coordinately expressed genes, many of 
which are epithelial-mesenchymal transition (EMT) markers including the EMT-inducing 
transcription factor Slug (SNAI2) [1]. The signature was derived using computational methods 
of systems biology after observing that the genes of the signature become significantly 
overexpressed only when cancer progresses to a particular invasive stage specific to each cancer 
type. For example, the gene signature is significantly triggered roughly when colon cancer 
progresses to stage II, ductal carcinoma in situ progresses to invasive ductal carcinoma of stage I, 
and ovarian cancer progresses to stage IIIc.    
We also found [2] that many of the genes of the signature, including α-SMA, and Slug being the 
only present EMT-inducing transcription factor, are expressed by the cancer cells themselves 
in vivo, and not by the peritumoral stoma, at least in one xenograft model of neuroblastoma that 
we tried, confirming that cancer cells have undergone a mesenchymal transition (the term EMT 
may not be accurate in this case, as the same signature is also present in nonepithelial cancers, 
such as neuroblastoma and Ewing’s sarcoma).  We refer to this multi-cancer signature as the 
“cancer mesenchymal transition signature.” It is characterized by a prominent presence of co-
expressed genes COL11A1, THBS2, INHBA. A set of the top 64 genes comprising the signature 
was presented in Table 1 of [2] (the number 64 is arbitrarily chosen as corresponding to the 
distinct genes from the top 100 probe sets originally presented   in [1]).  
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Results 
We used the 64 genes listed in Table 1 of [2] as input for Gene Set Enrichment Analysis (GSEA) 
provided by the Broad Institute against the Molecular Signatures Database (MSigDB) 
(www.broadinstitute.org/gsea/msigdb). The results included many “hits” with P value exactly 
equal to “zero,” providing biological insights into the nature of the underlying mechanisms. 
Among those (with “P = 0e0”), there were many occurrences of data sets of genes expressed in 
higher-stage samples from many cancer types, such as nasopharyngeal, head and neck, 
urothelial, lymphomas, etc. Such cancer types had not participated in any way whatsoever in the 
derivation of the signature. This remarkable validation of the signature by pointing to all kinds of 
cancer types in MSigDB suggests that the signature may reflect a universal biological 
mechanism present in the invasive stage of all solid cancers. The following table provides a 
sample of such GSEA results: 
 
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_UP 
[286] 
Genes up-regulated in nasopharyngeal 
carcinoma relative to the normal tissue. 
GRUETZMANN_PANCREATIC_CANCER_UP [346] Genes up-regulated in pancreatic ductal 
adenocarcinoma (PDAC) identified in a 
meta analysis across four independent 
studies. 
LINDGREN_BLADDER_CANCER_CLUSTER_2B [389] Genes specifically up-regulated in Cluster 
IIb of urothelial cell carcinoma (UCC) 
tumors. 
PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_ 
MA_UP [207] 
Up-regulated genes in angioimmunoblastic 
lymphoma (AILT) compared to normal T 
lymphocytes. 
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_ 
VE_UP [355] 
Genes up-regulated in invasive ductal 
carcinoma (IDC) relative to ductal 
carcinoma in situ (DCIS, non-invasive). 
VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARL 
ARLY_UP [167] 
Up-regulated genes distinguishing between 
two subtypes of gastric cancer: advanced 
(AGC) and early (EGC). 
CROMER_TUMORIGENESIS_UP [44] Tumorigenesis markers of head and neck 
squamous cell carcinoma (HNSCC): up-
regulated in the 'early' tumors vs normal 
samples. 
Discussion 
The epithelial-mesenchymal transition, when induced by transcription factors Snail or Twist, is 
known to generate cells with properties of stem cells [3]. As we show below in two examples, 
our computational results suggest that the same may also be true for the Slug-based 
mesenchymal transition reflected by this signature. 
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First, we found that the same set of 64 genes (in the form of a corresponding “metagene”) is 
associated with time to recurrence in glioblastoma [4]. Specifically, all glioblastoma patients 
with exceptionally long time to recurrence following treatment had exceptionally low levels of 
the signature. This is consistent with the hypothesized reduced stemness in the malignant cells of 
those patients. 
 
Second, we have also identified a “nonfibroblastic” version of the Slug-based EMT that only 
contains a subset of the 64 co-expressed genes [5], mainly SNAI2, DCN, LUM, COL1A1, 
COL1A2, COL3A1, COL6A3. This version is not necessarily associated with cancer; in fact the 
corresponding signature is differentially expressed even in normal tissues in a tissue specific 
manner [5], which may also induce cells to acquire stem cell properties: At one extreme, brain 
samples do not express the signature at all. At the other extreme, reproductive system samples 
do. This is consistent with the notion that stemness is most prominent in the cells of the 
reproductive system and least prominent in the highly differentiated cells of the brain. This lack 
of stemness in normal brain cells is also consistent with the above-mentioned association with 
prolonged time to recurrence in glioblastoma. 
 
Many cancer types have been classified into subtypes using traditional bioinformatics methods, 
such as non-negative matrix factorization consensus clustering, from rich gene expression data. 
These techniques often lead to the identification of mesenchymal “subtypes.” Our results suggest 
that these subtypes may simply be reflections of the fact that cancer cells have undergone a 
cancer mesenchymal transition reflected by the same core signature, though there are slight 
type-specific variations. In some cases there has been recognition that some cancer cells of 
“mesenchymal subtypes” may have undergone some transdifferentiation related to EMT. For 
example, the term “proneural-to-mesenchymal transition” [6] has been coined in glioblastoma. 
However, such transitions in solid cancers, including glioblastoma, may be amenable to being 
unified under the umbrella of the universal cancer mesenchymal transition signature. 
Interestingly, in glioblastoma the full signature is present but COL11A1 is not coexpressed as 
highly (perhaps because cancer cells do not encounter adipocytes [2]), while in other solid 
cancers COL11A1 is consistently the most reliable proxy of the signature.   
 
We found most of the genes in the signature expressed by cancer cells, but not by stromal cells, 
at least in one xenograft model [2] (though some genes of the signature, such as MMP11, were 
not expressed by the cancer cells). This suggests that the signature is largely produced by the 
cancer cells undergoing mesenchymal transition as a result of contextual microenvironmental 
interactions. However, related versions of the cancer mesenchymal transition signature have 
often been labeled as “stromal,” because the signature is fibroblastic and it is mostly found in the 
stroma following laser capture microdissection. Any presence of the signature in the tumor may 
then be interpreted as due to stromal infiltration. However, the truth may be exactly the opposite: 
the weak presence of the signature in the tumor may be genuine, as cancer cells start undergoing 
a mesenchymal transition. And the fully transdifferentiated, myofibroblast-like, cancer cells may 
well play the roles of cancer associated fibroblasts (CAFs) within the stroma [7]. Of course, the 
stroma contains fibroblasts from many other sources, some of which may express some of the 
genes in the signature. However, the remarkable co-expression of the genes in the particular 
mesenchymal transition signature may signify the presence of one of these sources as coming 
from the cancer cells themselves, resulting in a subpopulation of CAFs in the stroma that cannot 
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be easily distinguished from pure stromal cells. For example, the spindle-shaped cells expressing 
COL11A1 (the proxy of the mesenchymal transition signature) in Figure 2D of  
www.progenika.com/eu/images/stories/pdf/publicaciones/Barneo%20et%20al%20%20MIP%202006.pdf  
may conceivably be the transdifferentiated pancreatic cancer cells confused with desmoplastic 
stromal cells.  
 
It is believed [7] that EMT in cancer reactivates early embryogenesis programs. For example 
Slug is known to be active in the neural crest and was also found to be required for the metastasis 
of transformed melanoma cells [8]. By analyzing publicly available datasets, we further found 
that the “fibroblastic” Slug-based cancer mesenchymal transition signature (including COL11A1, 
etc.) is also highly enriched in the set of genes expressed by invasive trophoblasts during 
implantation in the maternal tissue. This finding suggests that invasive cancer cells undergoing 
mesenchymal transition may reactivate pathways of invasive trophoblasts involved in placental 
formation. Expression of Slug during implantation has already been known [9]. These concepts 
are strikingly reminiscent of the “trophoblast theory of cancer” proposed as early as 1902 by 
John Beard [10]. 
 
The cancer mesenchymal transition signature is found in significant amounts only if cancer has 
exceeded a particular invasive stage. On the other hand, the signature may or may not be 
detected in samples that have reached or exceeded this invasive stage. The absence of the 
signature in a particular high-stage sample does not necessarily imply that the signature had not 
been present earlier in time or at some other neighboring location in the heterogeneous tumor. 
It is also unclear to what extent the underlying mechanism of mesenchymal transition is causal 
for invasion and metastasis. It is conceivable, however, that, at least in some cases, it plays a 
causal role, leading to the exciting possibility that its inhibition may lead to reduction of 
recurrence and metastasis applicable to multiple cancer types.  
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